Cann Group Limited Overview
Cann Group was the first company in Australia to receive medicinal cannabis research and cultivation licences, in February and March 2017. It remains one of the country's few vertically integrated, GMP-certified producers of dried cannabis flower at industrial scale. Its core asset is a glasshouse cultivation and GMP manufacturing facility near Mildura, Victoria. It was built for about A$115–120m and designed for more than 12,500kg of dried flower a year, but it ran at roughly half of fitted capacity in FY26, producing 4.6 tonnes.
After a near-insolvency episode in 2024–25, the company completed a balance-sheet reset in December 2025. It discharged A$70.6m of National Australia Bank debt for A$15.3m, refinanced with a private credit fund and raised A$9.0m of equity. Revenue has nonetheless fallen for two years, to A$8.6m in FY26. The investment case now rests on export conversion (UK first, Germany next), utilisation of under-used GMP capacity, and possible strategic or M&A outcomes in a consolidating sector.
Company's own description
The FY26 announcements describe the business as follows (paraphrased). Cann aims to improve patients' lives by developing, producing and supplying innovative cannabis medicines. It operates a large-scale cultivation and GMP manufacturing facility with integrated research capability near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, plus bulk and white-label supply, it sells dried flower, oil, vape and edible medicinal cannabis products to customers in Australia and abroad (FY26 Results Announcement, 31 Aug 2026). Earlier boilerplate (FY25 to Nov 2025) also referred to active pharmaceutical ingredients, extracts and the Satipharm patent-protected capsule technology.
Independent characterisation
Cann is in practice a single-asset, cultivation-led medicinal cannabis manufacturer with an increasingly B2B mix. Revenue comes almost entirely from product sales: A$8.551m of A$8.563m in FY26. Services, mainly contract packing, contributed only A$0.012m in FY26, down from A$0.162m in FY25 (Appendix 4E Note 1).
The business model has moved through three phases:
2017–2021: a licence-holder and R&D platform. Revenue was negligible (A$0.56m in FY18), and Aurora-supplied product was used to serve the first patients.
2022–2024: a capex-heavy scale-up at Mildura funded by NAB construction debt. Revenue came from white-label oils, bulk and branded flower, alongside heavy losses.
2025–present: a restructured, cost-reset producer. Management has deliberately stepped back from low-margin white-label oil manufacturing and low-priced bulk channels to prioritise branded flower, B2B wholesale with minimum order quantities, and exports.
Revenue model mix (FY26, Appendix 4E and FY26 results)
| Revenue type | FY26 AUD Mn | Share of revenue | Comment |
|---|---|---|---|
| Product sales: dried flower | 7.7 | 90% | Botanitech (own-grown and curated), Mallee Bloom, bulk and white-label flower |
| Product sales: oils | 0.5 | 6% | Legacy white-label and branded oils, being de-emphasised |
| Product sales: other (vapes, gummies, capsules) | about 0.35 (derived residual) | about 4% | — |
| Services (contract packing) | 0.012 | <1% | GMP contract packing and white-label capability |
| Total revenue from customer contracts | 8.563 | 100% | — |
| Other income (R&D tax incentive and grants; other) | 1.089 | — | Not counted in revenue |
Subscription and licensing revenue: none disclosed.
Value-chain position
Cann covers most of the value chain:
-
genetics and breeding, including in-house strains La Bomba Ese and Lazer Fuel (AGM 2025);
-
tissue culture and mother-stock management;
-
cultivation;
-
post-harvest work (drying, with a move to a GMP hang-dry process, trimming and irradiation);
-
GMP packing.
For formulated products, it has historically relied on third-party contract manufacturers such as IDT Australia. Downstream it sells to:
-
wholesalers and distributors (bulk);
-
brand owners (white label);
-
prescriber-pharmacy channels in Australia under the TGA framework (Special Access Scheme / Authorised Prescriber pathways);
-
export importers in the UK, New Zealand and, prospectively, Germany and the wider EU.
Customer types and end-markets
Domestic B2B wholesalers and distributors: the largest channel by volume in FY26. Three customers each exceeded 10% of revenue, up from one in FY25.
Domestic pharmacy and patient (B2C brand) channel: Botanitech and Mallee Bloom, including supply agreements with 11 Chemist Warehouse outlets in Queensland on an initial two-year term (TipRanks summary of ASX release).
Export importers: UK (A$1.0m in FY26, the first year), New Zealand (A$0.36m) and Germany. AMRadV irradiation-related licences were secured in Q3 FY26 to support German and EU distribution.
End-markets: prescribed medicinal cannabis for chronic pain, anxiety, sleep and other indications under physician supervision.
Strategy
Stated strategic themes (FY26 Results, AGM 2025, Q3–Q4 FY26 4Cs)
-
A rebuilt balance sheet as a platform. The Chairman says FY26 rebuilt the balance sheet "to match the operating reset delivered in FY2025".
-
Export-led growth. The UK is established; Germany and the EU are in progress, using GMP certification as European buyers increasingly require pharmaceutical-grade, GMP-produced flower.
-
Strategic value of certified capacity. Management argues that global operators are competing to secure GMP-certified cultivation capacity, which re-rates the Mildura asset.
-
Margin over volume. Cann is exiting low-priced bulk and white-label oils and prioritising Botanitech own-grown flower, Mallee Bloom and exclusive genetics.
-
Cost discipline. The H2 exit run-rate of about A$12m sets the FY27 cost base.
-
Strategic partnering and M&A. Management continues to explore partnerships and transactions amid sector consolidation, and flagged an update before 30 June 2026.
Initiatives in the last 24 months
| Initiative | Date | Detail / target |
|---|---|---|
| Debt restructure and recapitalisation | Oct–Dec 2025 | NAB debt of A$70.6m settled for A$15.3m; A$14.75m private credit facility; A$9.0m equity |
| Organisational restructure | FY25–FY26 | Employee costs down 26% in FY26 |
| R&D relocation to Mildura | FY26 | Lower rent and overheads |
| GMP hang-dry transition | FY26 | Better terpene retention, lower microbial risk and export readiness |
| Rapid-drying technology trial | FY26 | Shorter drying cycles, microbial control and export formats |
| Plant-density optimisation study | FY26 | Maximise yield per m² |
| Yield improvement | FY25 | Wet-to-dry ratio raised from 7% to 13% (AGM 2025) |
| ERP and seed-to-sale migration to cloud | H2 FY26 | Compliance and inventory control |
| QA/QC process review | H2 FY26 | Export qualification |
| Inventory overhaul | H2 FY26 | Legacy stock rationalised; new stocktake methodology |
| Mallee Bloom launch | Q2 FY26 | Mid-price/premium Australian-grown brand |
| Gummies launch | Oct 2025 | New edible format |
| Chemist Warehouse supply (11 Queensland outlets) | 2,025 | Initial two-year term |
| UK export commencement | Q3 FY26 | A$1.0m in FY26 |
| German AMRadV licences | Q3 FY26 | Irradiation-licensing pathway for Germany |
| Convertible notes eliminated | 30 Jun – 3 Jul 2026 | Removes toxic-dilution overhang |
Guidance and targets
FY27: no quantitative guidance. Management reports a "very strong start": unaudited July revenue was well ahead of the prior year and export revenue stayed strong in August. It expects a material increase in production volume and operating leverage based on forward orders.
Superseded FY26 targets: (AGM 2025): revenue of about A$17m, EBITDA of A$0.3–0.7m and production of 7.7 tonnes. Actuals were A$8.56m, -A$3.7m and 4.6 tonnes.
Medium-term targets: not publicly disclosed.
ESG commitments: none publicly disclosed.
Products & Services
The portfolio is organised by channel because there is only one reporting segment. Pricing is not publicly disclosed for any SKU. Management sensitivity: every A$0.10/gram price increase adds about A$0.8m a year to profitability at 8 tonnes of production (AGM 2025).
Brands (B2C)
| Brand / product | Description | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Botanitech dried flower (own-grown) | Cann-bred, Mildura-grown high-THC and balanced flower, multiple THC/CBD SKUs | Prescribed patients via clinics and pharmacies | First in-house flower Mar 2022 | Own-grown Botanitech accounted for about 40% of 1H FY26 revenue (1H FY26 results). Revenue rose more than 100% YoY in FY25. |
| Botanitech curated range | Externally sourced (imported or third-party) flower sold under the Botanitech brand | Patients | — | Revenue fell 46% in 1H FY26 as Cann pivoted to own-grown |
| Botanitech oils | THC/CBD oil formulations | Patients | — | Oils total A$0.5m in FY26 |
| Botanitech vape cartridges | Vape carts | Patients | Product timeline 2023–2024 | Part of brand range (AGM 2025) |
| Botanitech / "Skylark" gummies | Edible format | Patients | Oct 2025 | First edible format (AGM 2025) |
| INC ("It's Not Craft") flower range | Value-oriented flower range | Price-sensitive patients | Brand timeline 2022–2025 | Named in AGM 2025 product timeline |
| NRG flower range | Flower range | Patients | Brand timeline | Named in AGM 2025 product timeline |
| Curated & VAL flower range | Value/curated flower | Patients | Brand timeline | Named in AGM 2025 product timeline |
| Mallee Bloom | Mid-price/premium, "Australian-owned and grown" flower brand | Patients wanting domestic provenance | Q2 FY26, with new SKUs added by Q4 FY26 | Launched in response to demand for Australian-grown flower |
| Satipharm CBD capsules | Patent-protected gelatin-matrix capsule delivery technology for CBD | Patients; international nutraceutical and medicinal markets | Acquired early 2021 | Still owned (1H FY26 boilerplate). Year-end inventory of "finished goods – capsules" was A$4.423m, though this label may be a legacy classification (see Section 6). |
Enterprise (B2B)
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Bulk dried flower | Wholesale supply of trimmed dried flower | Domestic distributors and brand owners; export importers | Highest B2B orders of FY26 came in Q3. Q1 FY26 was ahead of budget. Low-priced bulk is being deprioritised for margin. |
| White-label flower | Flower supplied under the customer's brand, with minimum order quantities | Brand owners without cultivation | New white-label customers signed in FY25. New strains sought on an exclusive basis. |
| White-label oils | Formerly contract-manufactured oils | Brand owners | Being exited because of low margins and stable demand (AGM 2025) |
| Contract packing | GMP-compliant automated packing lines | Third-party brands | FY26 service revenue was only A$12k |
| By-product monetisation | Trim sold for extraction; small buds sold as a value range | Extractors; value segment | AGM 2025 |
| Export flower (UK) | Dried flower meeting UK customer specifications | UK importers and distributors | A$1.0m in FY26, the first year |
| Export flower (NZ) | Dried flower | NZ distributors | A$0.36m in FY26 versus A$0.06m in FY25 |
| Export pathway (Germany / EU) | Irradiated flower under AMRadV licences; non-irradiated formats in development | German pharmacy-distribution importers | Pathway established. EU microbial specification work continues. |
Genetics
Cann maintains a proprietary breeding programme. Two strains, La Bomba Ese and Lazer Fuel, were in full production as of November 2025. Tissue culture is used for disease-free mother stock (FY26 Results).
Financial Narrative
Sources: FY2025–FY2026 from the Appendix 4E FY26 (unaudited FY26). FY2022–FY2024 from S&P Global Market Intelligence via StockAnalysis.com (data updated 31 Aug 2026). All figures in A$ millions unless stated.
Margins (chartable, % of revenue from customer contracts)
Revenue CAGR FY2022–FY2026: about 7.5% a year (A$6.41m to A$8.56m).
Revenue CAGR FY2024–FY2026: about -25.4% a year, reflecting two years of decline from the FY24 peak.
Non-recurring items bridge (FY2026)
Source: FY26 Results Announcement.
Balance sheet (chartable)
Total debt in FY2026 comprises the private credit refinancing loan (A$15.356m, non-current), the R&D tax incentive advance (A$0.469m), chattel mortgages (A$0.011m) and convertible notes (A$0.551m, current, redeemed 3 Jul 2026).
Cash flow (chartable)
FY2024 and FY2023 investing cash flows also included proceeds from asset sales of A$3.68m and A$3.07m respectively, consistent with the Southern facility disposal.
Ratios (chartable)
Net debt / EBITDA: is not meaningful in any year because EBITDA was negative.
ROE for FY2025: is not meaningful because equity was negative.
FY2026 ROE and ROA: are inflated by the A$55.3m non-cash debt-forgiveness gain. On normalised NPAT of -A$14.7m, ROE would be about -51% and ROA about -28%.
Cash conversion cycle:
-
Days sales outstanding on trade receivables: about 19 days in FY2025 and about 19 days in FY2026.
-
Inventory days against direct production costs: about 196 days in FY2025 and about 456 days in FY2026.
-
A meaningful cash conversion cycle cannot be computed, because the cost base is mostly fixed employee and facility costs and inventory includes legacy holdings.
Commentary on trends, inflections and drivers
Revenue. Revenue peaked at about A$15.4m in FY2024, after the Mildura ramp-up and heavy white-label oil and bulk activity. It then fell 26.5% in FY2025 and 24.2% in FY2026. Management attributes the FY26 decline to persistent price pressure in domestic dried flower and a deliberate exit from low-priced bulk and low-margin white-label oil.
The FY26 figure is a significant miss against guidance:
October/November 2025: revenue of about A$17m (+50%) and EBITDA of +A$0.3m to +A$0.7m (AGM 2025).
February 2026: EBITDA breakeven targeted for H2.
April 2026: guidance cut to A$9.2–10.0m with an EBITDA loss.
Actual: revenue A$8.56m and normalised EBITDA -A$3.7m.
Management credibility on forecasting is therefore a material analytical issue.
Cost base. The cost reset is real and verifiable in the statutory accounts. Operating costs before depreciation fell from A$22.2m in FY25 to A$14.7m in FY26, including the inventory write-down. Within that:
-
direct production costs fell 55%;
-
employee costs fell 26%;
-
administration fell 12%;
-
D&A fell 21%, partly because of the impairments.
H2 FY26 operating costs before D&A, write-down and R&D were A$6.0m, against A$7.0m in H1. That implies an annualised run-rate of about A$12m. At revenue of about A$8.6m, Cann still needs either about 40% more revenue at constant margin, or a mix shift to exports and branded flower, to reach EBITDA breakeven.
Balance sheet. FY26 is the inflection year. Total debt fell from A$75.8m to A$16.4m, current liabilities fell from A$80.9m to A$7.3m, and equity went from a deficiency of A$2.8m to A$29.1m. The cost was heavy dilution: shares on issue rose 161% in FY26, from 636m to 1,661m, and 3.7 times over two years. Mildura was also written down by a further A$19.0m. Its independent fair value under a fair-value-less-costs-to-dispose approach was A$50.6m at 30 June 2026, against A$70.2m a year earlier.
Cash flow. Operating cash burn fell 86%, from A$9.6m to A$1.3m. This was helped by a A$4.9m cut in cash interest and a A$2.3m R&D incentive receipt. The June 2026 quarter showed an operating cash inflow of A$0.24m (Q4 FY26 4C). Year-end cash was only A$0.49m, and the lender's A$250k minimum cash covenant was breached at certain points during the period. Liquidity remains extremely thin.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Dried flower revenue (AUD Mn) | — | 7.7 |
Oils revenue (AUD Mn) | — | 0.5 |
Products total (AUD Mn) | 11.138 | 8.551 |
Services, contract packing (AUD Mn) | 0.162 | 0.012 |
Total revenue from customer contracts (AUD Mn) | 11.300 | 8.563 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue from customer contracts (AUD Mn) | 15.37 | 11.30 | 8.56 |
YoY revenue growth (%) | 11.5 | -26.5 | -24.2 |
Operating result before finance costs, impairment and debt gain (AUD Mn) | -24.52 | -16.38 | -10.93 |
Operating margin (%) | -159.5 | -145.0 | -127.7 |
Normalised EBITDA, company definition (AUD Mn) | — | -5.0 | -3.7 |
Pre-tax income (AUD Mn) | -51.24 | -22.35 | 20.30 |
Segment Revenue
| AUD K | H1 FY26 | H2 FY26 | FY26 |
|---|---|---|---|
Revenue from customer contracts | 4,521 | 4,042 | 8,563 |
Administration and corporate costs | (2,044) | (1,955) | (3,999) |
Direct production costs (ex write-down) | (1,101) | (821) | (1,922) |
Employee costs | (3,869) | (3,238) | (7,107) |
Operating costs before D&A, write-down and R&D | (7,014) | (6,014) | (13,028) |
Inventory write-down | — | (1,737) | (1,737) |
Depreciation and amortisation | (3,642) | (2,215) | (5,857) |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customer contracts (AUD Mn) | 6.41 | 13.78 | 15.37 | 11.30 | 8.56 |
Other income incl. R&D incentive and grants (AUD Mn) | 4.83 | 6.86 | 2.99 | 1.95 | 1.09 |
Revenue less direct production costs (AUD Mn) | — | — | — | 3.20 | 4.90 |
Operating income before finance costs and one-offs (AUD Mn) | -24.25 | -29.73 | -24.52 | -16.38 | -10.93 |
Depreciation and amortisation (AUD Mn) | 4.80 | 11.96 | 11.04 | 7.44 | 5.86 |
EBITDA, derived as operating income plus D&A (AUD Mn) | -19.45 | -17.77 | -13.48 | -8.94 | -5.07 |
EBITDA normalised, company definition (AUD Mn) | — | — | — | -5.0 | -3.7 |
Interest / finance costs (AUD Mn) | 1.83 | 3.16 | 6.82 | 6.00 | 5.12 |
Pre-tax income (AUD Mn) | -26.47 | -33.79 | -51.24 | -22.35 | 20.30 |
Net income (AUD Mn) | -26.47 | -33.79 | -51.24 | -22.35 | 20.30 |
EPS basic (A$ cents) | — | — | — | -4.23 | 1.62 |
EPS diluted (A$ cents) | — | — | — | -4.23 | 1.62 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue less direct production costs margin (%) | — | — | — | 28.3 | 57.3 |
Operating margin (%) | -378.3 | -215.7 | -159.5 | -145.0 | -127.7 |
EBITDA margin, derived (%) | -303.4 | -129.0 | -87.7 | -79.1 | -59.2 |
Net margin (%) | -413.0 | -245.2 | -333.4 | -197.8 | 237.1 |
Key Financials
| Item (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Statutory NPAT | -22.3 | 20.3 |
Gain on bank debt forgiveness | 0 | 55.3 |
Gain on settlement of trade creditors | 0 | 0.3 |
Impairment of Mildura property, plant and equipment | 0 | -19.0 |
Inventory write-down | -3.9 | -1.7 |
Normalised loss after tax (company) | -18.5 | -14.7 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 139.66 | 129.47 | 92.77 | 78.79 | 51.99 |
Cash and equivalents (AUD Mn) | 1.91 | 0.77 | 1.64 | 0.01 | 0.49 |
Inventories (AUD Mn) | 10.67 | 11.41 | 8.51 | 4.34 | 4.58 |
Property, plant and equipment (AUD Mn) | 118.21 | 107.40 | 76.44 | 69.17 | 44.69 |
Goodwill and intangibles (AUD Mn) | 1.46 | 0.22 | 0.04 | 0.01 | 0.00 |
Short-term debt incl. current borrowings, leases and notes (AUD Mn) | 3.80 | 15.29 | 72.05 | 75.38 | 1.03 |
Long-term debt incl. leases and notes (AUD Mn) | 43.36 | 45.67 | 0.42 | 0.47 | 15.36 |
Total debt (AUD Mn) | 47.17 | 60.97 | 72.47 | 75.84 | 16.39 |
Net debt (AUD Mn) | 45.25 | 60.20 | 70.83 | 75.83 | 15.90 |
Total equity (AUD Mn) | 84.90 | 59.26 | 13.92 | -2.78 | 29.06 |
Working capital (AUD Mn) | 7.87 | -3.19 | -61.99 | -71.34 | -0.06 |
Shares on issue (millions) | 351.36 | 388.61 | 445.85 | 636.18 | 1,660.59 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -20.43 | -22.84 | -15.19 | -9.64 | -1.33 |
Capital expenditure (AUD Mn) | -45.16 | -3.10 | -2.51 | -0.16 | -0.41 |
Free cash flow (AUD Mn) | -65.60 | -25.94 | -17.69 | -9.80 | -1.74 |
Proceeds from share issues, net (AUD Mn) | 17.92 | 8.18 | 4.46 | 2.83 | 8.28 |
Net debt issued / (repaid) (AUD Mn) | 46.49 | 13.80 | 10.31 | 5.35 | -6.06 |
Cash interest paid (AUD Mn) | — | — | 4.57 | 5.46 | 0.54 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on ending equity (%) | -31.2 | -57.0 | -368.1 | — | 69.9 |
ROA on ending assets (%) | -19.0 | -26.1 | -55.2 | -28.4 | 39.0 |
ROIC, operating income / (equity + net debt) (%) | -18.6 | -24.9 | -28.9 | -22.4 | -24.3 |
Current ratio (x) | 1.70 | 0.87 | 0.21 | 0.12 | 0.99 |
Debt to equity (x) | 0.56 | 1.03 | 5.21 | — | 0.56 |
Interest coverage, operating income / finance costs (x) | -13.3 | -9.4 | -3.6 | -2.7 | -2.1 |
Asset turnover, revenue / ending assets (x) | 0.046 | 0.106 | 0.166 | 0.143 | 0.165 |
Revenue by Region and Revenue by Region (%)
| Region (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia, derived residual (AUD Mn) | 11.24 | 7.19 |
United Kingdom (AUD Mn) | 0 | 1.00 |
New Zealand (AUD Mn) | 0.06 | 0.36 |
Total international (AUD Mn) | 0.06 | 1.37 |
International share of revenue (%) | 0.5 | 16.0 |
Share Price History
| Date | Price (AUD) | Context / source |
|---|---|---|
3 May 2017 | 0.300 | IPO price |
26 May 2020 | 1.140 | Export agreements (FNN) |
31 Oct – 3 Dec 2025 | 0.0115 | Placement price |
8 Jan 2026 | 0.010 | Fintel |
16 Mar 2026 | 0.007 | Convertible announcement |
30 Jun 2026 | 0.002 | Price at release of redemption notice; 52-week low area |
31 Jul 2026 | 0.003 | StockAnalysis |
16 Sep 2026 | 0.005 | StockAnalysis (latest verified) |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market capitalisation | About A$8.3m | 1,660.6m shares |
Enterprise value | About A$24.2m | Market cap + A$16.39m debt − A$0.49m cash. About A$26m including the A$2m July 2026 facility increase, partly used to redeem the A$0.55m notes. |
P/E (statutory) | About 0.3x | Distorted by the A$55.3m gain; not meaningful |
P/E (normalised) | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | About 2.8x | On FY26 revenue of A$8.56m |
P/B | About 0.29x | On net assets of A$29.1m; NTA of A$0.0175 per share against a A$0.005 price |
Capital Instruments
| Instrument | Amount (AUD Mn) | Rate | Maturity |
|---|---|---|---|
Private credit refinancing loan | 15.36 carrying at 30 Jun 2026, plus up to 2.0 added Jul 2026 | 12.5% (9.5% cash + 3.0% PIK) | 31 Dec 2027 |
R&D tax incentive advance | 0.47 | 16% | 31 Oct 2026 (repaid from the R&D refund) |
Insurance premium funding | 0.01 | — | 31 Jul 2026 |
Chattel mortgages | 0.011 | — | Short-term |
Convertible notes | 0 (redeemed 3 Jul 2026) | — | — |
Analyst Conclusions
Management guidance
Management has given no quantitative FY27 guidance. Its qualitative outlook is:
-
a "very strong start", with July revenue well ahead of the prior year and export revenue strong into August;
-
a material increase in FY27 production volume and operating leverage, based on forward orders;
-
an FY27 cost base anchored on the H2 FY26 run-rate of about A$12m (operating costs before depreciation), plus a full year of lower interest.
There are no consensus estimates.
Bull case
-
Asset value far above the market price. The independent fair value of Mildura (A$50.6m) and net assets (A$29.1m) compare with a market capitalisation of about A$8m (0.29x book). A trade sale or partnership with a global operator seeking EU-GMP-capable capacity could re-rate the equity sharply.
-
Operating leverage at near-breakeven cash flow. With costs reset to about A$12m a year and Q4 FY26 operating cash flow already positive (A$0.24m), each extra tonne of export flower falls largely to EBITDA. The facility can produce well above 4.6 tonnes.
-
Export inflection. The UK went from zero to A$1.0m in one year; German licences are in hand; and Germany is Europe's fastest-growing medical cannabis market (LGP sold A$5.5m into Germany in one quarter). Exports were 16% of FY26 revenue and are reportedly accelerating.
Bear case
-
Revenue is still shrinking and guidance has been unreliable. FY26 revenue (A$8.56m) fell 24% and came in about 50% below the October 2025 target. The EBITDA-positive target became a A$3.7m loss.
-
Fragile liquidity and refinancing risk. Cash was A$0.49m at year end, covenant breaches needed waivers, and expensive 12.5% secured debt of about A$17m matures in December 2027. The going-concern emphasis of matter persists, and further equity raises at near-zero prices would add to dilution of more than 270% over two years.
-
Governance and execution gaps. There is no permanent CEO, the interim Executive Chair has a six-month term, and CEO turnover has been high (three CEOs since 2022). Customer concentration (three customers each above 10%) and single-site risk compound the problem.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Oct 2026 | Receipt of the A$0.62m R&D refund and repayment of the A$0.47m R&D loan |
| Late Oct 2026 | Q1 FY27 Activities Report / 4C: validation of the "very strong start" claim, export revenue and cash flow |
| Nov 2026 | 2026 AGM: auditor ratification, remuneration vote, possible board renewal; expiry or extension of the Executive Chair's six-month term (from 6 May 2026) |
| H2 CY2026 | Permanent CEO appointment |
| Any time | Outcome of the strategic partnering / M&A review (unconfirmed) |
| FY27 | First German export revenue; additional EU market approvals; non-irradiated flower specification |
| FY27 | Production volume against the 4.6-tonne FY26 base; capacity utilisation |
| Feb 2027 | 1H FY27 results: first half on the fully reset cost base |
| Ongoing | Covenant compliance and refinancing progress ahead of Dec 2027 |
Analyst verdict
Cann Group in October 2026 is a balance-sheet survivor with an operating business that has not yet earned its place.
The December 2025 NAB settlement was a decisive event for shareholders. It extinguished A$55.3m of debt, moved equity from a deficiency to A$29.1m, and cut cash interest by almost A$5m a year. Combined with a 34% reduction in operating costs, it brought the operating cash burn of a company that lost more than A$130m between FY2022 and FY2025 down to near breakeven. By any measure, that is a credible restructuring.
The commercial picture is weaker:
-
Revenue has fallen for two years running, to A$8.56m, which is below the scale of FY2023.
-
The FY26 targets presented to investors during the recapitalisation, roughly A$17m of revenue and positive EBITDA, were missed by wide margins.
-
The CEO who led the turnaround left within five months of completing it.
-
The facility ran at roughly half capacity, and domestic price pressure shows no clear sign of easing.
The equity is therefore best viewed as an option on two outcomes:
-
Organic export conversion. The UK, and potentially Germany, would need to absorb meaningfully more Mildura output at better prices than domestic bulk.
-
Strategic monetisation of a GMP-certified facility independently valued at about six times the market capitalisation.
The first outcome needs evidence over successive quarters, starting with the Q1 FY27 4C. The second depends on buyer appetite in a sector that is consolidating but still capital-constrained. Downside risks are substantial: thin cash, covenant fragility, 12.5% secured debt maturing in December 2027, a going-concern emphasis of matter and a history of dilutive funding. These mean that failure on either outcome would likely be resolved through further heavily dilutive capital or lender-led action.
On balance, Cann is a high-risk, special-situation exposure. Its discount to book is justified by execution and financing risk rather than mispricing alone. The most important near-term tests are:
-
Q1 FY27 export revenue and cash flow;
-
the appointment of a permanent CEO;
-
any concrete strategic transaction.
Each should be monitored closely before the turnaround thesis can be considered de-risked.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Mike Ryan | Executive Chairman (interim) | Chair since 28 Nov 2025; Executive Chair since 6 May 2026 (six-month initial term, extendable) | More than 40 years in financial services. Former head of equities at Shaw and Partners (6 years); 12 years at Goldman Sachs as executive director; executive director and head of distribution at Morgan Stanley. Chair of Sequoia Financial Group (ASX:SEQ); director of Energy One (ASX:EOL) and PM Capital Global Opportunities Fund (ASX:PFG). |
Steven Notaro | Company Secretary | — | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Background | Independence |
|---|---|---|---|
Mike Ryan | Executive Chairman | See above | Not independent while executive |
Doug Rathbone | Non-executive director (Chair until Nov 2025 AGM) | Former MD and CEO of Nufarm (about 40 years). Chairman of Rathbone Wine Group; director of Cotton Seed Distributors, Leaf Resources and AgBiTech; former CSIRO director. | Presumed independent |
Peter Kopanidis | Non-executive director | More than 30 years in finance: investor relations, treasury and corporate finance at Medibank, Telstra, Treasury Wine Estates and Foster's. Owner of Petra Investor Relations & Debt Advisory. Chartered Accountant; ex-KPMG. | Presumed independent |
Julian Chick | Non-executive director (per Dec 2024 insider trades) | Not detailed in the sources reviewed | — |
Robert Barnes | Non-executive director (per Dec 2024 insider trades) | Not detailed in the sources reviewed | — |
Major Shareholders
| Holder | Shares | % | Date of notice | Source |
|---|---|---|---|---|
Noble Investments Superannuation Fund Pty Ltd | 215,004,005 | 13.54 | 16 Jan 2026 | Market Index |
Regal Funds Management Pty Ltd and associates | 96,634,827 | 5.89 | 22 May 2026 | Market Index; became substantial 4 Dec 2025 |
Ryan Prue Pty Ltd | 18,450,000 | 1.16 | Mar 2026 | — |
Adsd Soodin Holdings Pty Ltd | 17,721,490 | 1.12 | Mar 2026 | Simply Wall St |
Gary Burg | 15,098,561 | 0.95 | Mar 2026 | Simply Wall St |
Philip Robert Jacobsen | 13,892,674 | 0.87 | Mar 2026 | Simply Wall St |
Competitive Landscape
Key Competitors
| Competitor | Type / segment overlap | Positioning relative to Cann |
|---|---|---|
Little Green Pharma (ASX:LGP) | Vertically integrated Australian and Danish producer; oils, flower, vapes; Europe | Far larger and profitable at the adjusted EBITDA level; ahead on European distribution |
Canopy Growth (TSX: WEED / Nasdaq: CGC) | Global cannabis; international medical exports | Global scale; competes in the UK, Germany and Australian import channels |
Tilray Brands (Nasdaq: TLRY) | Global medical cannabis, EU GMP production (Portugal, Germany) | — |
Aurora Cannabis (TSX/Nasdaq: ACB) | Global medical cannabis; Australian and EU presence | — |
Organigram (Nasdaq: OGI) | Canadian LP exporting to Australia and the EU | — |
Curaleaf International | European medical cannabis (UK, Germany) | — |
Cannatrek (private, Australia) | Domestic cultivator and brands | Direct domestic flower competitor |
Australian Natural Therapeutics Group (private) | Domestic cultivator | Direct domestic competitor |
Montu / Alternaleaf (private) | Telehealth prescribing and distribution platform | Controls patient demand; channel and customer as well as competitor |
Vitura Health (ASX:VIT) | Distribution and telehealth platform | — |
Bod Science (ASX:BOD) | CBD and medicinal cannabis products | — |
Imported Canadian, Portuguese and Colombian flower | Low-cost import supply | The main source of domestic price compression |
Peer Comparison FY2026
| Metric | Cann Group (FY Jun-26) | Little Green Pharma (FY Mar-26) | Canopy Growth (FY Mar-26) |
|---|---|---|---|
Revenue | A$8.56m | A$42.49m | C$284.6m (net) |
Revenue growth YoY | -24.2% | +15.3% | +6% |
Adjusted EBITDA | -A$3.7m (normalised) | +A$6.49m | -C$20.2m |
Adjusted EBITDA margin | -43% | +15% | -7% |
Statutory net result | +A$20.3m (one-offs) / -A$14.7m normalised | -A$1.41m | Net loss narrowed 49% (continuing operations) |
R&D intensity | About 0% (FY26 net benefit) | About 0.1% (A$0.05m) | — |
Operating cash flow | -A$1.33m | +A$0.04m | — |
Recent Developments
A Kalkine Media article dated 13 Jul 2026 refers to new UK/EU supply agreements.



